The Bahraini Genome Program is a comprehensive research program that divides participants into different categories and stages:
- In the first phase, 6,000 samples will be analyzed from participants in collaboration with Harvard University, and the analysis of the samples will be submitted by the end of this year, 2023.
- Participants will receive their individual results once the analysis and reporting process is completed by the team of specialized doctors.
- As for the second phase, 50,000 samples will be analyzed locally, and the timeline for this phase will be announced later.
The results of participants in the Bahraini Genome Program carry a high level of privacy, as individual health information is not sent through any means.
Participants will be personally notified and contacted when their sample analysis is completed by a team of experts. In the current stage,
the National Genome Centre is a research program. However, the National Genome Centre is committed to the responsibility of sharing results that have a sense of urgent
health importance and have actionable therapeutic and preventive plans.
If you wish to participate as an institution, contact The National Genome Centre to arrange a visit to the institution and organize a customized campaign for you.
The Bahraini Genome Program welcomes participants who are 21 years old and above. For those under 21 years old,
they can participate after obtaining written consent from their parents and filling out the participation form.
No. Research genome projects aim to benefit the health outcomes of individuals irrelevant to their race or ancestry.
Through this program, the participant will be able to know their genetic health mutations, which helps in creating personalized medicine and pharmacogenomics options
and the correct medication to avoid unexpected side effects based on each individual’s genetic makeup. Furthermore, it helps in determining their genetic status related
to carrying mutations or genetic variations that can cause diseases and whether they can be inherited by their offspring or not. Moreover, the overall personal benefits
of participation include the healthcare system's ability to implement preventive and therapeutic measures based on the genetic map of Bahrain
Join us to reach the goal of 50,000 samples by the end of 2023!
Preliminary studies have shown that the following diseases are the most common in the initial batches of samples,
and more will be revealed in the upcoming stages with the completion of the National Genome Project:
- Genetic blood disorders: Sickle cell anemia, thalassemia, and others.
- Cancer tumors: Hereditary breast and ovarian cancer.
- Genetic heart diseases: Hypertrophic cardiomyopathy.
